Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Renier Brentjens
Sloan Kettering Inst Can Research, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Juno Therapeutics
Equity Interest - Publicly traded entity (e.g., stock, stock option, or other ownership interest)
MUC16 is being used in this research. MUC16 has been licensed to Juno.
Immunologic Approaches to Ovarian Cancer
Cancer Immunotherapy has been identified as the scientific breakthrough of 2013 by Science Magazine. This proposal contains four tightly linked projects addressing Ovarian Cancer Immunotherapeutics. The projects range rom direct antibody imaging and therapy with MUC16/CA125 antibodies to personalized vaccine therapy, immune checkpoint inhibitors and treatment with specially modified patient T cells. The overall goal of the project is to improve the cure rate and the symptom free survival of women with advanced ovarian cancer.
Filed on November 09, 2018.
Tell us what you know about Renier Brentjens's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Renier Brentjens”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Renier Brentjens | Sloan Kettering Inst Can Research | Conflict of Interest | Juno Therapeutics | >$600,000 |
| Renier Brentjens | Sloan Kettering Inst Can Research | Conflict of Interest | Juno Therapeutics | $60,000 - $79,999 |
| Renier Brentjens | Sloan Kettering Inst Can Research | Conflict of Interest | Juno Therapeutics | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.